Want to see TSE:TLT full AI Analyst Report?

Theralase Technologies (TLT) Price & Analysis

96 Followers

TLT Stock Chart & Stats

C$0.28

C$0.00(0.00%)

At close: Jan 08 4:00 PM EST

C$0.28

C$0.00(0.00%)

Day’s Range― - ―

52-Week RangeC$0.15 - C$0.41

Previous CloseN/A

Volume127.37K

Average Volume (3M)121.23K

Market Cap

C$75.40M

Enterprise ValueC$72.37

Total Cash (Recent Filing)C$1.00M

Total Debt (Recent Filing)C$431.58K

Price to Earnings (P/E)―

Beta-0.18

Next Earnings

Aug 31, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding295,671,330

10 Day Avg. Volume149,922

30 Day Avg. Volume121,227

Financial Highlights & Ratios

PEG Ratio1.28

Price to Book (P/B)23.49

Price to Sales (P/S)51.16

P/FCF Ratio-12.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$0.70

Price Target Upside150.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.02

Revenue Forecast (FY)C$1.25M

Bulls Say, Bears Say

Bulls Say

Revenue & Gross Margin RecoveryA meaningful rebound in TTM revenue and gross margin suggests durable improvements in product mix or pricing power. Higher margins expand the path to profitability by requiring less revenue to cover fixed costs, supporting longer-term sustainability if growth continues.

Low Leverage / Manageable Balance SheetA low debt-to-equity ratio and modest absolute debt give the company financial flexibility to fund clinical development or commercialization without immediate solvency pressure, reducing bankruptcy risk and preserving optionality for strategic investments.

Niche Photomedicine SpecializationA focused business model in laser-based photomedicine and PDT targets specialized clinical niches with high barriers to entry, meaningful IP/technical know-how and clear regulatory pathways, supporting longer-term competitive differentiation versus generic device makers.

Bears Say

Persistent Negative Cash FlowSustained negative operating and free cash flow (~-$3.2M TTM) creates ongoing funding needs and increases dilution or financing risk. Over a multi-month horizon, reliance on external capital can constrain strategy and delay clinical or commercial milestones.

Deep Negative ProfitabilityExtremely negative net margins indicate the current cost structure vastly exceeds revenue. This undermines return metrics and requires substantial, sustained revenue growth or cost reduction to reach break-even, raising long-term viability concerns if trends stall.

High Execution And Funding RiskLarge net losses combined with cash burn create execution risk: management must deliver commercial progress or secure financing. With a small organization and early-stage commercialization, missed milestones or funding gaps could materially delay growth and dilute shareholders.

Theralase Technologies News

Theralase Posts 100% Preclinical Response in Muscle Invasive Bladder Cancer Study

Theralase Technologies ( ($TSE:TLT) ) has provided an update. Theralase Technologies reported that its X-ray-activated Rutherrin compound achieved...

3M ago

Theralase Raises C$2.66 Million to Advance Bladder Cancer Drug Programs

Theralase Technologies ( ($TSE:TLT) ) has issued an announcement. Theralase Technologies has raised C$2.66 million through a non-brokered...

3M ago

Theralase Uncovers New Antiviral Mechanism for Ruvidar Against Herpes Virus

Theralase Technologies ( ($TSE:TLT) ) just unveiled an update. Theralase Technologies has identified an additional mechanism by which...

4M ago

Theralase Raises C$1.1 Million to Advance Bladder Cancer Trial

An update from Theralase Technologies ( ($TSE:TLT) ) is now available. Theralase Technologies has closed a non-brokered private...

4M ago

Theralase’s Rutherrin Boosts Radiation Efficacy in Muscle Invasive Bladder Cancer Models

The latest update is out from Theralase Technologies ( ($TSE:TLT) ). Theralase Technologies has reported new preclinical data...

5M ago

Theralase Preclinical Data Backs Ruvidar–Interferon Combo for Bladder Cancer

An announcement from Theralase Technologies ( ($TSE:TLT) ) is now available. Theralase Technologies has reported preclinical in vitro...

5M ago

Theralase Preclinical Data Backs Ruvidar–Interferon Combo in Bladder Cancer

Theralase Technologies ( ($TSE:TLT) ) just unveiled an announcement. Theralase Technologies reported new preclinical data showing that its...

5M ago

Theralase Bladder Cancer Data Heads to Major Urology Congress as Regulatory Plans Advance

The latest announcement is out from Theralase Technologies ( ($TSE:TLT) ). Theralase Technologies’ interim clinical data for its...

5M ago

Theralase Bladder Cancer Data to Headline 2026 European Urology Congress

The latest announcement is out from Theralase Technologies ( ($TSE:TLT) ). Theralase Technologies’ interim clinical data for its...

5M ago

Theralase Bladder Cancer Data to Debut at 2026 European Urology Congress

Theralase Technologies ( ($TSE:TLT) ) has issued an announcement. Theralase Technologies’ interim clinical data on its light-activated Ruvidar...

5M ago

TLT FAQ

What was Theralase Technologies’s price range in the past 12 months?

Theralase Technologies lowest stock price was C$0.14 and its highest was C$0.41 in the past 12 months.

What is Theralase Technologies’s market cap?

Theralase Technologies’s market cap is C$75.40M.

When is Theralase Technologies’s upcoming earnings report date?

Theralase Technologies’s upcoming earnings report date is Aug 31, 2026 which is in 39 days.

How were Theralase Technologies’s earnings last quarter?

Currently, no data Available

Is Theralase Technologies overvalued?

According to Wall Street analysts Theralase Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Theralase Technologies pay dividends?

Theralase Technologies does not currently pay dividends.

What is Theralase Technologies’s EPS estimate?

Theralase Technologies’s EPS estimate is >-0.01.

How many shares outstanding does Theralase Technologies have?

Theralase Technologies has 295,671,330 shares outstanding.

What happened to Theralase Technologies’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Theralase Technologies?

Currently, no hedge funds are holding shares in TSE:TLT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Theralase Technologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

31.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.

Theralase Technologies (TLT) Earnings & Revenues

Historic Earnings Reports

TLT Stock 12 Month Forecast

Average Price Target

C$0.70

▲(150.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","1":"C$1","-1":"-C$1","-0.5":"-C$0.5","0.5":"C$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$0.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$0.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$0.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.255,0.28923076923076924,0.32346153846153847,0.35769230769230764,0.39192307692307693,0.4261538461538461,0.46038461538461534,0.49461538461538457,0.5288461538461537,0.563076923076923,0.5973076923076923,0.6315384615384615,0.6657692307692307,{"y":0.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.255,0.28923076923076924,0.32346153846153847,0.35769230769230764,0.39192307692307693,0.4261538461538461,0.46038461538461534,0.49461538461538457,0.5288461538461537,0.563076923076923,0.5973076923076923,0.6315384615384615,0.6657692307692307,{"y":0.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.255,0.28923076923076924,0.32346153846153847,0.35769230769230764,0.39192307692307693,0.4261538461538461,0.46038461538461534,0.49461538461538457,0.5288461538461537,0.563076923076923,0.5973076923076923,0.6315384615384615,0.6657692307692307,{"y":0.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.195,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.215,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.155,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.165,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.305,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.255,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >